Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

Equipping Healthcare Professionals with the Necessary Tools for Improving Care in Ovarian Cancer

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Applying Evidence and Expert Experience to Optimize Management and Overcome Challenges in CLL

Wednesday, May 18, 2022, 12:30 PM - 1:30 PM CT
  -  Register

 

 

Activity Description

This program presents the latest clinical data to aid pharmacists in providing optimal care for their patients with CLL/SLL, including downloadable slides with PracticePoints based on presentations from a live, 1-hour webinar, and a ClinicalThought commentary with key take-home points and FAQs from the webinar.

Target Audience

The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with CLL as well as other stakeholders in hematology/oncology practice.

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Devise treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference.
  • Evaluate intraclass differences for agents with similar therapeutic targets in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles.
  • Plan strategies by which hematology-oncology pharmacists can optimize outcomes for patients with CLL/SLL, including addressing adverse event management, medication adherence, and minimizing potential drug–drug interactions.
  • Examine the evolving role of measurable residual disease, fixed duration treatment plans, and CAR T-cell therapy in CLL/SLL care.

Faculty

Lydia Benitez, PharmD, BCOP
Adult Outpatient Leukemia Pharmacist Specialist
Michigan Medicine
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Caitlin R. Rausch, PharmD
Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Houston, Texas

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-162-L01-P has been assigned to this live knowledge-based activity (initial release date 5-18-2022). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.

Funding

This activity is supported by an educational grant from AbbVie Inc.

 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.